UNSPSC 51422355: Methylprednisolone sodium phosphate

This classification denotes a therapeutic glucocorticoid C22H29O8P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6089CVN95V, chemically known as pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-6-methyl-21-(phosphonooxy)-, disodium salt (6.alpha.,11.beta.)-, but more generally known as methylprednisolone sodium phosphate, which bears US NIH Compound Identifier 21115. European Medicines Agency schedules Methylprednisolone sodium phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25642.

UNSPSC 51422355 Methylprednisolone sodium phosphate is a Commodity code that, based on recent state and local solicitations, maps poorly to actual procurement activity under it. The code's nominal scope describes a specific corticosteroid pharmaceutical product, but the two most recent opportunities posted under this code involve naloxone procurement and pharmacy benefit management strategy — neither of which is methylprednisolone sodium phosphate or directly related to it. State and local governments clearly tag medications and pharmacy services across the broader pharmaceutical taxonomy with varying precision, and this code shows little recent activity that aligns with its stated commodity scope. Issuing bodies posting under the code span county health departments (Seminole County, Florida) and state health agencies (Texas Health and Human Services Commission), but the mismatch between the code label and the actual work solicited suggests misclassification rather than genuine procurement demand for this particular steroid formulation.

The geographic spread of recent activity includes Florida and Texas, with no other states represented in the current opportunity set. The only concrete solicitation with a fixed response deadline is Seminole County's IFB60459723LAS, an invitation for bids posted June 30, 2026, for naloxone and drug deactivation systems with a response deadline of July 26, 2026 — an activity unrelated to methylprednisolone. The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, as a market-intelligence request regarding direct-to-manufacturer prescription programs, also unrelated to this specific pharmaceutical. The code appears to be either misapplied by issuing bodies or carries limited relevance to current state and local procurement in methylprednisolone sodium phosphate itself. Business development professionals tracking this code should verify whether opportunities are genuinely tagged as methylprednisolone sodium phosphate or whether the code represents a broader pharmaceutical procurement category with inconsistent application.